Evidence map›Paper›PMID 39554253›Full record

ArticleJournal of translational autoimmunity2024

C3 glomerulopathy is highly prevalent in French Polynesia.

Nelly Candela, Nicolas Benichou, Mathilde Lefebvre, Lorraine Gueguen, Paula Vieira-Martins, Carine El Sissy, Hervé Sartelet, Pascale Testevuide, Ronan Delaval, Stanislas Faguer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational autoimmunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nelly CandelaService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Nicolas BenichouService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Mathilde LefebvreService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Lorraine GueguenService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Paula Vieira-MartinsLaboratoire d'Immunologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.
Carine El SissyLaboratoire d'Immunologie, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Paris, France.
Hervé SarteletLaboratoire d'anatomopathologie, CHU de Nancy, Nancy, France.
Pascale TestevuideService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Ronan DelavalService de Néphrologie, Centre Hospitalier du Taaone, Tahiti, French Polynesia.
Stanislas FaguerDépartement de Néphrologie et Transplantation d'organes, Centre de Référence des maladies rénales rares, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To compare the natural history of C3 glomerulopathy (C3G) to acute post-infectious glomerulonephritis (APIGN) in a cohort of patients with a relative homogeneity of environment conditions and genetic background. Methods: We retrospectively reviewed the characteristics of all patients with biopsy proven C3G or APIGN referred in 2013-2019 to the only renal unit in French Polynesia. Results: Point prevalence of C3G is ∼23 cases per 100,000 inhabitants. A recurrent variation of CFI (p.Arg406His) was identified at the heterozygous state in 4/8 (50 %) patients with C3G but its pathogenicity remain elusive. Characteristics at presentation and kidney outcomes were roughly similar between C3G (n = 16) and APIGN (n = 20), excepted for the presence of humps on kidney biopsy. Conclusions: C3G is highly prevalent in French Polynesia suggesting specific genetic or environmental susceptibility factors. Systematic diagnosis workflow should be proposed to all patients with C3 predominant glomerulonephritis.

Indexed as

Acute post-infectious glomerulopathyC3 glomerulonephritisComplement alternative pathwayComplement factor I

Identifiers

PMID39554253
PMCPMC11565528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.